Shots:

• Apobiologix expands its footprints in Canada with the approval of Bambevi + CT to treat colorectal- lung- brain and ovarian cancer
• The approval is coupled with well-established Apobiologix supportive care products that enable the company to transform access to affordable therapies in oncology and other indications
• In 2016- Apobiologix launched its first product- Grastofil (filgrastim) followed by the launch of Lapelga in 2019 in Canada. Additionally- Apobiologix is the first company to offer a portfolio of G-CSF biosimilars

  | Ref: Newswire | Image: Biospace